MAPT and Alzheimer disease: The early clinical trials for one of the tau ASOs in early-stage AD (BIIB080 developed by Biogen) did not show any serious adverse effects in patients and efficiently lowered CSF tau, which was used as a proxy for brain tau levels [186].